ALUNBRIG (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ALUNBRIG
Date registered
Evaluation commenced
Decision date
Approval time
165 (255 working days)
Active ingredients
brigatinib
Registration type
EOI
Indication
ALUNBRIG (tablet) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).